Compare Dow Jones Industrial Average ETF (DIA) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Cassava Sciences Inc — how do they compare? Dow Jones Industrial Average ETF trades at $516.07 (market cap $45.20B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Dow Jones Industrial Average ETF is far larger — about 1147.2× Cassava Sciences Inc's market cap, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and Cassava Sciences Inc for 37 Days on average.
| DIA | FLNA | |
|---|---|---|
Market Cap | $45.20B | $39.40M |
Volume | 4,095,368 | 759,018 |
52-Week High | $542.79 | $4.64 |
52-Week Low | $451.37 | $0.68 |
Typical Hold Time | 104 Days | 37 Days |
Sector | — | Health |
Enterprise Value | — | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $516.07, up 0.99% with bearish technical signals from moving averages. The ETF maintains dividend distributions with three recent payouts scheduled through October 2026. Market sentiment reflects broader volatility concerns amid economic uncertainty and Fed policy speculation.
The ETF's outlook remains tied to Dow component performance, with technical resistance at $516 limiting near-term upside. Dividend consistency provides income stability, though bearish momentum and market-wide pressures pose headwinds for large-cap value exposure.
FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.
While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
